METHODS
Serum samples were obtained from a longitudinal prospective cohort including GCA and TAK patients from multiple centers located in the United States and Canada. This study is in compliance with the Declaration of Helsinki and has been approved by the local institutional review board. All patients met either the modified American College of Rheumatology criteria for GCA or the modified American College of Rheumatology criteria for TAK. 14, 15 Active disease was defined as a Birmingham Vasculitis Activity Score version 1 score greater than 0 and a physician's global assessment greater than 0. The serum concentrations of S100A8/ S100A9 heterodimers and S100A12 were measured by enzyme-linked immunosorbent assay. 11 Comparisons were made to S100A8/S100A9 levels in healthy, historical control subjects (n = 35) measured in the same laboratory using a 2-tailed Student t test.
11
A mixed-effects model was used to compare average levels of S100A8/S100A9 or S100A12 in active and inactive disease states. The qualities of predictions of disease activity from these models using either the traditional measures (ESR and CRP) or the 2 new measurements (S100A8/S100A9 and S100A12) were assessed using receiver operating characteristic curves with confidence intervals (CIs) using the DeLong approach. A significance level of 5% was used for all testing.
RESULTS

Giant Cell Arteritis
Serum samples were obtained from 59 patients with GCA (Table) . The majority of patients were female (74.6%) and white (98.3%). Forty-two patients (71%) had positive temporal artery biopsies diagnostic for GCA. Forty-six patients (78%) had samples drawn during both active and inactive disease. Serum S100A8/ S100A9 and S100A12 levels were measured on 50 samples during active disease and 56 samples during inactive disease. The mean serum levels of S100A8/S100A9 and S100A12 were both significantly higher during active disease compared with inactive disease; S100A8/S100A9: 1445.6 ng/mL (95% CI, 1189.2-1757.1) versus 1095.7 ng/mL (95% CI, 910.7-1318.3 ng/mL), p = 0.003; S100A12: 163.2 ng/mL (95% CI, 124.3-214.2 ng/mL) versus 116.6 ng/mL (95% CI, 90.3-150.6 ng/mL), p = 0.016. Mean S100A8/S100A9 and S100A12 levels (including both active and inactive disease) were significantly higher compared with those of control subjects; S100A8/S100A9: 305 ng/mL (95% CI, 246.2-363.8 ng/mL); S100A12: 40 ng/mL (95% CI, 20.4-59.6 ng/mL). An area under the curve (AUC) of 0.61 was obtained using the combination of S100A8/S100A9 and S100A12, which was not statistically different for a model using the combination of ESR and CRP (AUC, 0.73; p = 0.13). A model utilizing all variables increased the AUC to 0.79 (Fig.) .
Takayasu Arteritis
Serum samples were obtained from 16 patients with TAK (Table) . The majority of patients were female (87.5%) and white (93.8%). The mean age when the serum was collected was 35 years (range, 19-65 years). There was a non-statistically significant increase in S100A8/S100A9 levels during active disease compared with levels during inactive disease: 1028 ng/mL (95% CI, 640-1652 ng/mL) versus 843 ng/mL (95% CI, 536-1327 ng/mL), p = 0.38. There were no differences in the S100A12 levels between active and inactive disease (86.8 ng/mL [95% CI, 50.2-150.6 ng/ mL] vs. 85.1 ng/mL [95% CI, 47.9-151.1 ng/mL], p = 0.93). Mean S100A8/S100A9 and S100A12 levels (including both active and inactive disease) were significantly higher compared with control subjects. None of the biological markers (CRP, ESR, S100A8/ S100A9, or S100A12) significantly correlated with disease activity in logistic regression models for each of these measurements.
When comparing GCA with TAK, there were no significant differences between the means (including both active and inactive disease) for either S100A8/S100A9 ( p = 0.1130) or S100A12 ( p = 0.0734).
DISCUSSION
This is the first study to investigate the role of S100 proteins as a marker of disease activity in primary large vessel vasculitis. In GCA, both S100A8/S100A9 and S100A12 were significantly higher during active disease compared with inactive disease and control subjects. The S100 proteins better predict disease activity when combined with traditional biomarkers (ESR and CRP) compared with using traditional biomarkers alone. While the S100 proteins did not outperform the traditional biomarkers, we suspect that the ability of traditional biomarkers to predict disease activity was overestimated because physicians rely on both ESR and CRP for disease assessment. In TAK, this study is the first to demonstrate that both S100A8/S100A9 and S100A12 are higher in patients compared with control subjects, with a trend toward S100A8/S100A9 being higher during active disease. This may have some future implication in the pathogenesis of large vessel vasculitis, and future studies should explore this pathway.
There are several strengths to this study including this being a large registry of patients from multiple centers, the prospective nature of the assessment, all S100 protein measurements done in the same laboratory, and 71% of GCA patients were biopsy proven. The primary limitation is the inability to determine to what degree the traditional biomarkers influenced the physicians' assessment of disease activity.
There is a critical need to develop better methods of assessing disease activity in both GCA and TAK. Our group has demonstrated that gene expressions of S100A8, S100A9, and S100A12 are increased in the GCA temporal arteries, 12 even in arteries that did not show inflammation. This suggests S100 proteins may be elevated early on in disease flares, possibly rising earlier than 
